Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345382 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL2169970 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL8653916 | 0.90 | ALDH1A1 (0.48) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL1115743 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308568 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL309095 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308565 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL31206852 | 0.84 | CA12 (0.45) | CA1CA2CA9PYGBGAA | |
| SCHEMBL22346509 | 0.83 | CA12 (0.48) | CA1CA2CA9PYGBGAA | |
| SCHEMBL23066316 | 0.81 | PYGB (0.41) | CA1CA2CA9PYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4689127-A1 | RF1 KO E. COLI STRAINS | Sutro Biopharma, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | SUTRO BIOPHARMA, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4651906-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | Ambrx, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250302915-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE DAMAGE AND ARTHRITIS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| WO-2006069246-A9 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | AMBRX, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | AMBRX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | AMBRX, INC. (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194256-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | CA1 2859/4885CA2 2778/4885CA9 1468/4885 |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | IFNG, IFNAR1, EIF2AK2 | CA1 4774/4885CA2 4797/4885CA9 4254/4885 |
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | GHITM, GHRHR, GHSR | CA1 3379/4885CA2 3366/4885CA9 1910/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | CA1 1380/4885CA2 2642/4885CA9 1565/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | CA1 2190/4885CA2 1027/4885CA9 615/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | CA1 3088/4885CA2 3819/4885CA9 2191/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | CA1 1917/4885CA2 3727/4885CA9 2488/4885 |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | CD22, FCGR3B, FCGR2A | CA1 612/4885CA2 961/4885CA9 699/4885 |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | GHRHR, VEGFA, SHBG | CA1 1936/4885CA2 3670/4885CA9 1576/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | CA1 4606/4885CA2 4788/4885CA9 3869/4885 |
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | VSIG8, F13B, HNRNPH3 | CA1 2062/4885CA2 3939/4885CA9 2356/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | CA1 3426/4885CA2 2367/4885CA9 2006/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | CA1 4043/4885CA2 3933/4885CA9 4135/4885 |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | DAO, DNPEP, PTMS | CA1 1575/4885CA2 2262/4885CA9 1390/4885 |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | GHITM, HDGF, GHRHR | CA1 2240/4885CA2 4045/4885CA9 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.